Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07667803 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
A Phase 3 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,500
- Enrollment target
NCT07667803: Recruiting Phase 3 study, sponsored by AstraZeneca.
NCT07667803 is a Phase 3 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (483% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07667803, a Phase 3 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,500 participants
- Enrollment target
Study Summary
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).
Primary Outcome
Percent change from baseline to Week 72 in body weight
Interventions
- DRUG Placebo
- DRUG Elecoglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 3 |
What NCT07667803 shows while recruiting
NCT07667803 is an interventional study that assigns participants to a tested intervention. Its 4,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (483% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07667803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07667803 about?
NCT07667803 is a clinical study titled "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM". This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exerci...
What is the current status of trial NCT07667803?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,500 participants. The study started on 2026-06-29. Estimated completion is 2029-07-30.
What interventions are being tested in trial NCT07667803?
The interventions under investigation include: Placebo (DRUG), Elecoglipron (DRUG).
Who is sponsoring clinical trial NCT07667803?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07667803's enrollment target sits among peer trials
4,500 55th of 2000 higher than 1,945 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- NCT07207564 · 4,500 participants
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI